Category Archives: ALS Treatment

Global Prostacyclin Market Forecast to 2025 is a new research released at Market Study Report and provides information about industry Top Key Players, Countries, Type and Application. This Prostacyclin report also states Company Profile, sales, Prostacyclin Market revenue and price, market share, market growth and gross margin by regions, Strategic recommendations for the new entrants, Market forecasts for a minimum of five years of all the mentioned segments, sub segments and the regional markets. Continue reading →

SAN DIEGO--(BUSINESS WIRE)--Neuropore Therapies, Inc. announced today that it has successfully completed the Phase 1 clinical trial in healthy volunteers with NPT520-34. Continue reading →

I agree that I have read this Consent Form and by providing my personal information and clicking SIGN UP FOR UPDATES I understand and agree that Mitsubishi Tanabe Pharma America, Inc. Continue reading →

Other names: ALS; Lou Gehrig's Disease; Motor Neurone Disease About Amyotrophic Lateral Sclerosis: A disease of the motor nerve cells in the brain and spinal cord, causing progressive loss of motor control. Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and the Sean M. Healey & AMG Center for ALS at Mass General today announced that AMX0035 demonstrated a significant treatment benefit for people with ALS in the CENTAUR study. In the study, participants taking AMX0035 had a statistically significant slowing of ALS disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) compared to placebo (p Continue reading →

Wow, its beautiful! said Aylajoy Dufresne, 5, who wore a pink tutu, as she ran to princess Elena of Avalor and hugged her. Elena! I wasnt expecting all this, said her mother, Cassy Dufresne. Continue reading →

December 23, 2019 02:11 ET | Source: AB Science multilang-release Paris, 23 December 2019, 8.15am New results published in the peer-reviewed journal Glia further support masitinibs potential mode of action in ALS AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication by an international team of researchers of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis (ALS) that further reinforces the rationale for masitinibs potential neuroprotective effect in ALS. The publication, led by researchers from the Institut Pasteur de Montevideo, the University of Alabama at Birmingham (UAB), the Oregon State University (OSU) and the IMAGINE Institute of Paris, is entitled, Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL34, and SCF in amyotrophic lateral sclerosis. Continue reading →

Chris Snow took over as the Calgary Flames assistant GM for the 2019-20 season (photo: Calgary Flames). Chris Snow, a former Boston Globe writer and NHL executive with the Calgary Flames and Minnesota Wild, has been diagnosed with ALS. Kelsie Snow, the wife of the 38-year-old, wrote on NHL.com that her husband already has been part of a clinical trial to try and treat the illness. Continue reading →

Kadimastem plans to submit an amendment to the protocol of its ongoing Phase 1/2a trial in Israel assessing the use of AstroRx, an off-the-shelf stem cell therapy, for the treatment of amyotrophic lateral sclerosis (ALS). The company wants to change the planned dosage in one of the studys cohorts and test repeated injections of a low dose of AstroRx, instead of the medium dose that was originally planned. The request is based on positive interim data from the first set of five patients given a single intrathecal (into the spinal canal) injection of the lowest dose (100 x 106 cells) of AstroRx. Continue reading →

By Debra Morgan, WRAL anchor/reporter Raleigh, N.C. A Duke University doctor who treats ALS patients is excited and hopeful after documenting cases in which patients who have the condition have seen it vanish. Continue reading →